跳至主要内容
临床试验/NCT05950490
NCT05950490招募中不适用

Construction of Diagnosis and Treatment System for Primary Vitreoretinal Lymphoma

Peking Union Medical College Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
1
主要终点
Interleukin-10/Interleukin-6(IL-10/IL-6)

研究概览

简要总结

This study intends to apply for the establishment of research beds, establish a Chinese PVRL research cohort, and carry out a to achieve the following research objectives:

The goal of this prospective observational study is to construct the diagnosis and treatment system for primary vitreoretinal lymphoma(PVRL). The study is to achieve the following research objectives:

  1. To establish a comprehensive diagnostic criteria for PVRL with high diagnostic efficiency and strengthen the PVRL diagnostic system;
  2. To establish a standardized treatment pathway for PVRL and evaluate the efficacy and safety of treatment;
  3. To screen the prognosis evaluation indicators, and to establish the follow-up process and prognosis evaluation system of PVRL;
  4. To explore the pathogenesis of PVRL, specific tumor markers and drug therapeutic targets.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Newly diagnosed PVRL patients admitted to the Ophthalmology or Hematology departments of Peking Union Medical College Hospital from 2022 to 2024;
  • 18-75 years old;
  • The diagnosis was confirmed by pathology, aqueous humor/vitreous IL-10/IL-6, vitreous flow cytometry and gene rearrangement.;
  • HIV-Ab negative;
  • Creatinine clearance > 50ml/min;
  • Sign informed consent.

排除标准

  • Combined with other tumors;
  • Uncontrolled active infections;
  • Pregnant or lactating women;
  • Antitumor therapy other than the protocol of this study was used.

研究组 & 干预措施

Group A

Cerebrospinal fluid IL-10 was normal

干预措施: Intravitreal injection of methotrexate (Drug)

Group B

Cerebrospinal fluid IL-10 was normal or elevated

干预措施: Intravitreal injection of methotrexate (Drug)

结局指标

主要结局

Interleukin-10/Interleukin-6(IL-10/IL-6)

时间窗: 2.5 years

cerebrospinal

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验